ArticleCancer medicine2023
Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population-based self-controlled case series.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiacChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Cancer-Related Immune Therapies: Bidirectional Implications From Cardiotoxicity to Emerging Cardiovascular Therapeutics: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Association between immune checkpoint inhibitors and cardiovascular risks: a nationwide self-controlled case series study.American journal of cancer research · 2025Article
- Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else.Investigational new drugs · 2024Article
- Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis: A systematic review and meta-analysis.Cancer innovation · 2024Article
- Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study.Cancer medicine · 2024Article
- Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome.Life (Basel, Switzerland) · 2024Article
- Temporal trends in guideline-recommended cardiometabolic testing completeness before initiating immune checkpoint inhibitors: A cohort study.Journal of internal medicine · 2024Article
- Association between immune checkpoint inhibitors and myocardial infarction in Asians: A population-based self-controlled case series.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile immune checkpoint inhibitors (ICIs) are associated with elevated cardiovascular risks, evidence of any association between ICIs and myocardial infarction (MI) was scarce, especially in Asians.
methodsUsing prospectively collected population-based data, this self-controlled case series included patients prescribed an ICI between 1/1/2014 and 31/12/2020 in Hong Kong who had MI within January 1, 2013 to December 31, 2021. Incidence rate ratios (IRRs) for MI during and after ICI exposure were estimated, compared to the year before ICI initiation.
resultsOf 3684 identified ICI users, 24 had MI during the study period. MI incidence increased significantly in the first 90 days of exposure (IRR 3.59 [95% confidence interval: 1.31-9.83], p = 0.013), but not days 91-180 (p = 0.148) or ≥181 (p = 0.591) of exposure, nor postexposure (p = 0.923). Sensitivity analyses excluding patients with MI-related death and incorporating extended exposure periods produced consistent results separately.
conclusionsICIs were associated with increased MI incidence in Asian Chinese patients during the first 90 days of use, but not later.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.